pamapimod has been researched along with Diabetes-Mellitus--Type-2* in 2 studies
2 other study(ies) available for pamapimod and Diabetes-Mellitus--Type-2
| Article | Year |
|---|---|
Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern.
The SARS-CoV-2 pandemic remains a major public health threat, especially due to newly emerging SARS-CoV-2 Variants of Concern (VoCs), which are more efficiently transmitted, more virulent, and more able to escape naturally acquired and vaccine-induced immunity. Recently, the protease inhibitor Paxlovid Topics: Antiviral Agents; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Pioglitazone; Pyridones; Pyrimidines; SARS-CoV-2 | 2022 |
Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.
Activation of various interacting stress kinases, particularly the c-Jun N-terminal kinases (JNK), and a concomitant phosphorylation of insulin receptor substrate 1 (IRS-1) at serine 307 play a central role both in insulin resistance and in β-cell dysfunction. IRS-1 phosphorylation is stimulated by elevated free fatty acid levels through different pathways in obesity. A series of novel pyrido[2,3-d]pyrimidin-7-one derivatives were synthesized as potential antidiabetic agents, preventing IRS-1 phosphorylation at serine 307 in a cellular model of lipotoxicity and type 2 diabetes. Topics: Diabetes Mellitus, Type 2; HEK293 Cells; Humans; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Serine | 2016 |